CD19/22 CAR-T cell therapy for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a special cell therapy that targets two markers on cancer cells to treat certain blood cancers. It may help people whose cancer has not gotten better with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 6 months old.
- Your cancer cells must have a specific marker called CD19 or CD22 (your doctor can test for this).
- You should be generally well and able to do daily activities (a score of 80 or higher on the Karnofsky scale).
- Your blood count (hemoglobin) should be at least 80 g/L (your doctor will check).
- You must not have an active infection, HIV, hepatitis B or C, and you must not be pregnant or breastfeeding.
- You should not have had both CD19 and CD22 CAR-T cell therapy before, and you should not be on steroids for at least a week before treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins (CD19 and CD70) on your cancer cells. It is for patients with B-cell cancers that didn't respond to previous treatments.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
This trial tests a new car t-cell treatment for people with certain blood cancers that did not go away or came back after standard treatments. It aims to see if this therapy can help when other options have not worked.
This trial tests a new type of CAR-T therapy (a treatment that trains your immune cells to attack cancer) for people with certain types of B-cell leukemia that are CD19 negative or have relapsed after CD19 treatment. It may help if your cancer has other markers like CD22 or CD123.
This trial tests a personalized cell therapy that uses your own immune cells, modified to better find and attack lymphoma cells. It may help when standard treatments have not worked.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.